Esperoct is now approved in Canada for the treatment of haemophilia A in both children and adults

12 July 2019 - New treatment can help Canadians living with haemophilia A better manage their bleeding episodes ...

Read more →

ADMA Biologics receives FDA approval for license transfers for Bivigam and Nabi-HB

8 July 2019 - All aspects of the Biotest Therapy Business Unit acquisition are successfully completed. ...

Read more →

Grifols announces FDA approval of Xembify, 20% subcutaneous immunoglobulin for primary immunodeficiencies

4 July 2019 - Xembify is Grifols’ first 20% subcutaneous immunoglobulin for the treatment of primary immunodeficiencies. ...

Read more →

Esperoct (turoctocog alfa pegol, N8-GP) approved in the EU

20 June 2019 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Esperoct for the treatment ...

Read more →

FDA approves prior approval supplement for Bivigam

10 May 2019 - ADMA Biologics announces that the U.S. FDA has approved the Company’s prior approval supplement for Bivigam (immune ...

Read more →

PHARMAC fully funding innovative improvements in haemophilia treatment

30 April 2019 - PHARMAC has today provided haemophilia patients fully funded access to new innovative treatment options which will ...

Read more →

FDA approves Asceniv, a novel intravenous immune globulin

1 April 2019 - Approved for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to ...

Read more →

Decision to make changes to funded haemophilia treatments

8 March 2019 - PHARMAC is pleased to announce changes to funded haemophilia treatments that will result in two new ...

Read more →

Novo Nordisk receives US FDA approval of Esperoct (turoctocog alfa pegol, N8-GP)

19 February 2019 - Novo Nordisk today announced that the US FDA has approved the biologics license application for Esperoct ...

Read more →

Proposal for changes to funded haemophilia treatments

29 January 2019 - PHARMAC is proposing to make changes to the funding of haemophilia treatments from 1 May 2019, ...

Read more →

ADMA Biologics submits response and provides supplemental information to FDA for Bivigam complete response letter

7 January 2019 - ADMA Biologics announces that the Company has submitted responses to the U.S. FDA complete response letter received ...

Read more →

ADMA Biologics provides regulatory update on Bivigam PAS submissions

19 December 2018 - FDA issues complete response letter for drug substance, approves supplement for drug product. ...

Read more →

FDA promotes the development and adoption of innovations that can ensure the continued safety of the U.S. blood supply

4 December 2018 - Today the U.S. FDA updated a draft guidance entitled, “Bacterial Risk Control Strategies for Blood Collection Establishments ...

Read more →

Data from patient registries to replace clinical trials in previously untreated haemophilia patients

30 November 2018 - EMA has published revised guidelines on the tests and studies needed to support marketing authorisation applications ...

Read more →

Bayer receives EU approval for its haemophilia A treatment Jivi

27 November 2018 - The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical ...

Read more →